<DOC>
<DOCNO>EP-0651801</DOCNO> 
<TEXT>
<INVENTION-TITLE>
POLYPEPTIDES HAVING SEROTONINERGIQUE ACTIVITY (5HT5A), NUCLEIC ACIDS CODING FOR THESE POLYPEPTIDES AND USES THEREOF
</INVENTION-TITLE>
<CLASSIFICATIONS>C07H2104	G01N3353	C07K14705	C12N1512	C12Q168	C12N1512	A61K3800	C12N1509	C07H2100	C12Q168	C12N510	C12N1509	C12N510	G01N3353	C07K1472	A61P4300	A61K3800	C07K14435	A61P4300	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07H	G01N	C07K	C12N	C12Q	C12N	A61K	C12N	C07H	C12Q	C12N	C12N	C12N	G01N	C07K	A61P	A61K	C07K	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07H21	G01N33	C07K14	C12N15	C12Q1	C12N15	A61K38	C12N15	C07H21	C12Q1	C12N5	C12N15	C12N5	G01N33	C07K14	A61P43	A61K38	C07K14	A61P43	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Novel polypeptides designated 5HT5a having serotoninergic receptor activity, genetic material for their expression, any recombinant cell expressing said polypeptides, and uses thereof are disclosed.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
INST NAT SANTE RECH MED
</APPLICANT-NAME>
<APPLICANT-NAME>
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
AMLAIKY NOURDINE
</INVENTOR-NAME>
<INVENTOR-NAME>
BOSCHERT URSULA
</INVENTOR-NAME>
<INVENTOR-NAME>
HEN RENE
</INVENTOR-NAME>
<INVENTOR-NAME>
PLASSAT JEAN-LUC
</INVENTOR-NAME>
<INVENTOR-NAME>
AMLAIKY, NOURDINE
</INVENTOR-NAME>
<INVENTOR-NAME>
BOSCHERT, URSULA
</INVENTOR-NAME>
<INVENTOR-NAME>
HEN, RENE
</INVENTOR-NAME>
<INVENTOR-NAME>
PLASSAT, JEAN-LUC
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
A polypeptide comprising the peptide sequence SEQ ID No. 1.
A polypeptide according to claim 1, 
characterized in that
 it has the capacity to
bind serotonin.
A polypeptide according to claim 2, 
characterized in that
 it has serotonin
receptor activity.
A polypeptide according to one of claims 1 to 3, 
characterized in that
 it can be
recognized by antibodies which recognize the peptide sequence SEQ ID No. 1.
A polypeptique comprising the sequence SEQ ID No. 7.
A nucleotide sequence coding for a polypeptide according to one of claims 1 to
5.
A sequence according to claim 6, 
characterized in that
 it is selected from:

(a) the nucleotide sequence SEQ ID No. 1 or its complementary strand,
(b) any sequence hybridizing with a sequence (a) and coding for a polypeptide
according to one of claims 1 to 5, and
(c) the sequences derived from the sequences (a) and (b) as a result of the
degeneracy of the genetic code.
A sequence according to claim 7, 
characterized in that
 it comprises the
nucleotide sequence SEQ ID No. 7.
A sequence according to claim 7, 
characterized in that
 it is selected from
genomic, cDNA or RNA sequences, hybrid sequences, synthetic and semisynthetic

sequences. 
A sequence according to one of claims 6 to 9, 
characterized in that
 the part
coding for the said polypeptide is placed under the control of signals permitting

its expression in a cell host.
An antisense oligonucleotide capable of at least partially inhibiting the
production of polypeptides according to one of claims 1 to 5, 
characterized in
that
 it consists of a nucleotide sequence according to claim 7.
A nucleotide probe capable of hybridizing with a sequence according to claim
7 or with the corresponding mRNA, 
characterized in that
 it comprises the
nucleotide sequence SEQ ID No. 1, the nucleotide sequence SEQ ID No. 7 or

their complementary strands.
A nucleotide probe capable of hybridising with a sequence according to claim
7 or with the corresponding mRNA, 
characterized in that
 it is selected from the
sequences SEQ ID No. 5, 6, 8-11.
In vitro
 use of a probe according to claim 12 or 13 as an agent for detecting
the expression of a 5HT5a serotonin receptor, for demonstrating genetic

abnormalities (incorrect splicing polymorphism, point mutations, and the like), for
identifying neurological, cardiovascular or psychiatric disorders as being

associated with 5HT5a receptors, or for demonstrating and isolating homologous
nucleic acid sequences coding for 5HT5a polypeptides.
Expression vector, 
characterized in that
 it contains a nucleotide sequence
according to one of claims 6 to 10.
A recombinant cell capable of expressing at its surface a polypeptide
according to one of claims 1 to 5, 
characterized in that
 it contains an expression
vector according to claim 15. 
A recombinant cell according to claim 16, 
characterized in that
 it is selected
from eukaryotic cells and prokaryotic cells.
A method for demonstrating and/or isolating ligands of the polypeptides as
defined in claims 1 to 5, 
characterized in that
 the following steps are carried out:

a molecule or a mixture containing different molecules which are possibly
unidentified, is contacted with a recombinant cell according to claim 16

expressing at its surface a polypeptide as defined in claims 1 to 5, under
conditions permitting interaction between the said polypeptide and the said

molecule, and
the molecules bound to the said polypeptide are detected and/or isolated.
A method according to claim 18 for demonstrating and/or isolating agonists
or antagonists of serotonin.
A method for demonstrating and/or isolating modulators of the polypeptides
as defined in claims 1 to 5, 
characterized in that
 the following steps are carried
out:


a molecule or a mixture containing different molecules which are possibly
unidentified, is contacted with a recombinant cell according to claim 16

expressing at its surface a polypeptide as defined in claims 1 to 5, in the
presence of 5HT, under conditions permitting interaction between the said

polypeptide and 5HT, and
the molecules capable of modulating the activity of 5HT with respect to the
said polypeptide are detected and/or isolated.
</CLAIMS>
</TEXT>
</DOC>
